New cell therapy targets stubborn leukemia after transplant
NCT ID NCT07280494
Summary
This early-phase study is testing a new type of CAR-T cell therapy for patients with T-cell leukemia or lymphoma. The goal is to see if it is safe and effective at eliminating tiny amounts of leftover cancer cells that remain after a patient has already received a stem cell transplant. The therapy involves a single infusion of specially engineered immune cells designed to target the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD7+ T-ALL/LBL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, China, 100044, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.